BioSpace News Archive

Ionis Pharmaceuticals, Inc. announced that management will participate in fireside chats at the following investor conferences.

Frequency Therapeutics, Inc. today announced that members of its management team will participate in investor and medical conferences later this month.

C2N Diagnostics, a leader in advanced brain health diagnostics, and Healius Ltd (ASX:HLS), one of Australia’s leading listed healthcare companies, today announced a partnership that will aim to bring C2N’s PrecivityAD™ blood test and related brain health biomarkers to the forefront of memory and dementia care in Australia.

Codiak BioSciences, Inc. announced a reprioritization of its clinical and research initiatives, an acceleration of discussions related to potential strategic corporate and program-based partnerships, and a restructuring of operations to support a streamlined set of priorities.

The global endoscopic vessel harvesting systems market is projected to expand at a CAGR of 1.5% over the forecast period.

The widely available diabetes drug metformin reduced serious COVID outcomes by more than half if started within 4 days of symptoms, in a large, double-blind, randomized, controlled trial conducted by the University of Minnesota and published Aug. 18 in the New England Journal of Medicine, according to the Parsemus Foundation.

Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematology and oncology, recently announced its interim results for the six months ended June 30, 2022.

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and operational highlights for the period ended June 30, 2022 and provided an update on upcoming milestones.

InnoCare Pharma (HKEX: 09969) announced today the acceptance of the biologics license application (BLA) for tafasitamab in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT) by the Department of Health, the Hong Kong Special Administrative Region, China.

The global clinical chemistry analyzers market was valued at ~US$ 11.3 Bn in 2021. The clinical chemistry analyzers market is projected to expand at a CAGR of ~4% from 2022 to 2030.